Hospira, Vertex top analyst forecasts in Q2; U.S. Senate panel looks into contact-lens pricing;

Sales

@FiercePharma: Popular on FiercePharmaMarketing: Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton

@EricPFierce: Hikma builds more heft in sterile manufacturing. Say it will take equipment out of closed Ben Venue plant. News | Follow @EricPFierce

@CarlyHFierce: Today in FiercePharmaMarketing: Doom for combo meds? PBMs dump 2-in-1 drugs; 'Name-calling' at FDA. Issue | Follow @CarlyHFierce

> Hospira's ($HSP) second-quarter profit more than doubled, easily beating out analysts' expectations. Report (sub. req.)

> Vertex ($VRTX) posted a wider Q2 loss, topping analyst forecasts. Report

> A U.S. Senate panel will take a look at price-setting for contact lenses. Report

> The European Commission (EC) has approved Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) Eliquis for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE. Release

> India's Lupin expects its domestic sales to grow 18% to 20% in fiscal 2015. Report

> Record physician demand drove a 27% increase in U.S. net Feraheme revenues for Amag Pharmaceuticals ($AMAG). Release

> GlaxoSmithKline's ($GSK) once-weekly diabetes treatment Tanzeum is now available in pharmacies in the U.S. Release

Medical Device News

@FierceMedDev: Dental implant player Nobel Biocare is the latest med tech M&A target. Story | Follow @FierceMedDev

@StacyALawrence: Large healthcare customers squeeze med tech supplier Owens & Minor. Article | Follow @StacyALawrence

@VarunSaxena2: AcelRx discusses sublingual painkiller's rejection with concerned investors. FierceDrugDelivery article | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: Epic Sciences ropes in $PFE and $RHHBY funding to commercialize CTC tests for cancer treatment. FierceDiagnostics story | Follow @EmilyWFierce

> Kickstarter in vogue as funding mechanism for new devices. Story

> What will changes to the Sunshine Act mean for devicemakers? Item

> Coloplast adding 150 jobs in the U.K. to boost chronic care business. Article

Biotech News

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: I used to make fun of $PFE's big in-licensing deals (remember Medivation and Alzheimer's?) I'm switching to out-licensing now (neratinib). | Follow @JohnCFierce

@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. More | Follow @DamianFierce

@EmilyMFierce: Ebola treatments caught in limbo. Nature piece | Follow @EmilyMFierce

> Sanofi, Regeneron prep their PCSK9 cardio contender for FDA review after PhIII sweep. Report

> Gilead bags a portfolio of HIV-neutralizing antibodies. Item

> Immuno-oncology partnering-palooza continues with Genentech, AstraZeneca deals. Article

Drug Delivery News

> Amid fears of shortage of antibiotics, DNA origami technique developed to combat E. coli, other bugs. Article

> Nanoparticles deliver agents to spur immune system into action against cancer. Story

> Developer of unique delivery technology for eye care expanding in Europe. Item

> Nature-inspired artificial cilia could help move drugs to a target. More

> AcelRx discusses sublingual painkiller's rejection with concerned investors. Article

Diagnostics News

> In Q2, diagnostics venture investment showed some signs of life. More

> Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table. Article

> Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test. Story

> Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. Article

> Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device. Item

Pharma Marketing News

> Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs. Report

> Name-calling: The FDA needs your ideas for locking down brand monikers. More

> AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits. More

> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story

> Merck spokeswoman: Sales layoffs to hit PA-based field reps. Article

And Finally... A gene tied to negative thoughts and impulses may help researchers create a blood test predicting suicide risk. Story